Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
•Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placebo •Topline data expected in 2026
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more